文献速递头颈外科

HPV相关口咽癌不同治疗方式的胃造瘘管依赖与患者报告生活质量:系统综述与荟萃分析

Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis.
PubMed 文献 · Head Neck · 2021-07-29

结果显示两组胃造瘘管依赖率在12个月和24-36个月均无统计学显著差异,但手术联合辅助治疗组在12个月时的UW-QOL吞咽和总体评分更差。

要点

  • 手术联合辅助治疗与顺铂化放疗的胃造瘘管依赖率在12个月和24-36个月均无显著差异。
  • 手术联合辅助治疗组12个月时UW-QOL吞咽评分和总体评分均显著低于顺铂化放疗组。
  • 需进一步随机对照试验直接比较HPV相关口咽癌治疗后的功能结局。

核心结论

  • 手术联合辅助治疗与顺铂化放疗在胃造瘘管依赖率上无统计学显著差异。
  • 手术联合辅助治疗在部分患者报告的吞咽和总体功能指标上差于顺铂化放疗。

研究设计与样本

  • 评估治疗结束后1-3年的功能结局。

主要发现

  • 12个月胃造瘘管依赖率:手术联合辅助治疗8.3%(95% CI: 3.1-15.9) vs. 顺铂化放疗4.2%(95% CI: 1.1-9.2),p=0.37。
  • 24-36个月胃造瘘管依赖率:手术联合辅助治疗10.5%(95% CI: 3.2-21.5) vs. 顺铂化放疗3.3%(95% CI: 2.0-4.9),p=0.06。
  • 12个月UW-QOL吞咽评分:手术联合辅助治疗84(95% CI: 80-88) vs. 顺铂化放疗89(95% CI: 87-90),p=0.03。
  • 12个月UW-QOL总体评分:手术联合辅助治疗76(95% CI: 72-80) vs. 顺铂化放疗84(95% CI: 81-86),p=0.001。

临床怎么用

  • 临床决策时应考虑手术联合辅助治疗可能带来更差的患者报告吞咽和总体功能结局。
  • 胃造瘘管依赖风险在两种治疗方式间无显著差异,可结合其他因素个体化选择。

局限性

  • 需要进一步随机对照试验直接比较HPV相关口咽癌治疗后的功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We examined the impact of treatment modality on gastrostomy tube dependence and patient-reported outcomes in human papillomavirus-associated oropharyngeal cancer (HPV-OPSCC). We performed systematic review and meta-analysis of functional outcomes 1-3 years after treatment. Twenty-three studies were included, reporting on 3127 patients treated for HPV-OPSCC. Gastrostomy tube dependence failed to show statistically significant difference between surgery with adjuvant therapy and chemoradiotherapy with cisplatin at 12 months (8.3% [95% CI: 3.1-15.9] vs. 4.2% [1.1-9.2], p = 0.37) and 24-36 months (10.5% [95% CI: 3.2-21.5] vs. 3.3% [2.0-4.9], p = 0.06). Surgery with adjuvant therapy was associated with worse University of Washington Quality of Life (UW-QOL) Swallowing (84 [95% CI: 80-88] vs. 89 [87-90], p = 0.03) and UW-QOL Overall scores (76 [95% CI: 72-80] vs. 84 [81-86], p = 0.001) compared to chemoradiotherapy with cisplatin at 12 months. Surgery with adjuvant therapy was associated with worse performance on certain measures of patient-reported swallow and overall function compared to chemoradiotherapy with cisplatin. Further randomized controlled trials are needed to directly compare functional outcomes after treatment for HPV-OPSCC.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Quan DL, Sukari A, Nagasaka M, et al. Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head Neck. 2021. PMID: 34323332. doi:10.1002/hed.26829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。